Sonoma Pharmaceuticals Investor Presentation — November 2017 - Sonoma Pharmaceuticals, Inc.

Document content

SONOMA PHARMACEUTICALS

SECOND QUARTER FY2018 RESULTS

Welcome / Introduction

September 30, 2017 Highlights

Marc Umscheid Brand Building and Biz Development

Financial Review Bob Miller

2 Page Forward -Looking Statement

Except for historical information herein, matters set forth in this press release are forward -looking within the meaning of the “safe

harbor” provisions of the Private Securities Litigation Reform Act of 1995 , including statements about the commercial and

technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”) .

These forward -looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others .

Forward -looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business

that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may

change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or

approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent

applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products

will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues

will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product

formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and

other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission . The Company

disclaims any obligation to update these forward -looking statements, except as required by law.

3 Page Results from the Quarter Ended 30 September 2017

Total Net Revenue = $ 4,325,000

•Up 55% versus same period last year

•Up 13% versus quarter ended 30 Jun

4 US Dermatology Revenue = $ 1,621,000

•Up 53% versus same period last year

•Up 36% versus quarter ended 30 June 2017

EBITDA during the period = ($ 2,276,000)

Cash & cash equivalents = $9,983,000

Preview truncated — download the full document for the complete content.